FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199336306> ?p ?o ?g. }

• W3199336306 abstract "Objective: To determine morphological and biological control as well as toxicity and quality of life (QoL) of men with localized prostate cancer (PCa) treated with MRI-guided focal boost radiotherapy. Material and Methods: 30 patients with PCa and a visible dominant intraprostatic lesion (DIL) identified on mpMRI were included in a prospective Phase II trial. Matching point registration of planning CT and T2W, diffusion-weighted and a gradient-recalled echo (GRE) MRI images made in treatment position was used for prostate and tumour delineation. Treatment consisted on 35 daily fractions of 2.17 Gy with a concomitant focal boost to the DIL of 2.43 Gy using volumetric modulated arc therapy (VMAT) and image-guided radiation therapy (IGRT) with intraprostatic fiducial markers. Biochemical failure was analysed using PSA nadir +2 ng/mL criteria and local control using mpMRI evaluation at 6–9 months following RT. Acute and late toxicity were defined according to CTCAE v.4.0 and RTOG/EORTC scales and QoL was assessed using IPSS, EPIC short-form and UCLA-PCI questionnaires. Results: The median radiation dose to the prostate was 77.6 Gy (IQR 77.3–78.1), and to the DIL was 85.5 Gy (IQR 85.0–86.0). With a median follow up of 30.0 months (IQR 25.5–40.27), all patients remain free of biochemical relapse. An mpMRI complete response was observed in 25 patients during the first post-treatment evaluation at 6 months. The remaining five patients achieved a complete disappearance of the DIL both on T2 and DWI on the second mpMRI performed at 9 months following treatment. Six out of 30 (20%) patients presented acute Grade 2 urinary toxicity with no Grade 3 acute complications. Acute rectal toxicity was only found in 2 (6.6%) patients (both Grade 1). Only late Grade 1 urinary and rectal complications were observed in 3/30 patients, respectively, with no Grade 2 or more late toxicity. The urinary, bowel and sexual bother EPIC scores were slightly and insignificantly increased in the first 3 months post-treatment, returning to normal afterwards. Conclusions: mpMRI-guided focal boost using VMAT hypofractionated technique is associated with an excellent morphological and functional response control and a safe toxicity profile. Advances in knowledge: In the present trial, we examined the potential role of mpMRI for radiological assessment (functional and morphological) of treatment response in high-risk prostate cancer patients treated with MRI-guided focal radiotherapy dose intensification to dominant Intraprostatic lesion." @default.
• W3199336306 created "2021-09-27" @default.
• W3199336306 creator A5008589447 @default.
• W3199336306 creator A5021638987 @default.
• W3199336306 creator A5027831576 @default.
• W3199336306 creator A5032217039 @default.
• W3199336306 creator A5038153105 @default.
• W3199336306 creator A5044140135 @default.
• W3199336306 creator A5054640090 @default.
• W3199336306 creator A5062168165 @default.
• W3199336306 creator A5083780722 @default.
• W3199336306 creator A5087739701 @default.
• W3199336306 date "2022-03-01" @default.
• W3199336306 modified "2023-10-10" @default.
• W3199336306 title "MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial" @default.
• W3199336306 cites W1992743783 @default.
• W3199336306 cites W1998201907 @default.
• W3199336306 cites W2014695103 @default.
• W3199336306 cites W2029852561 @default.
• W3199336306 cites W2033645471 @default.
• W3199336306 cites W2043883020 @default.
• W3199336306 cites W2055033467 @default.
• W3199336306 cites W2078968196 @default.
• W3199336306 cites W2085845883 @default.
• W3199336306 cites W2102283130 @default.
• W3199336306 cites W2110839901 @default.
• W3199336306 cites W2110881680 @default.
• W3199336306 cites W2124539070 @default.
• W3199336306 cites W2125878029 @default.
• W3199336306 cites W2147303790 @default.
• W3199336306 cites W2282402220 @default.
• W3199336306 cites W2285254902 @default.
• W3199336306 cites W2346331092 @default.
• W3199336306 cites W2427718155 @default.
• W3199336306 cites W2605357195 @default.
• W3199336306 cites W2799363517 @default.
• W3199336306 cites W2800014774 @default.
• W3199336306 cites W2891148018 @default.
• W3199336306 cites W2894079334 @default.
• W3199336306 cites W2896758702 @default.
• W3199336306 cites W2928985222 @default.
• W3199336306 cites W2952903287 @default.
• W3199336306 cites W2973514824 @default.
• W3199336306 cites W2975799947 @default.
• W3199336306 cites W2994487010 @default.
• W3199336306 cites W2994914410 @default.
• W3199336306 cites W2999177950 @default.
• W3199336306 cites W3000928905 @default.
• W3199336306 cites W3021441388 @default.
• W3199336306 cites W3092285337 @default.
• W3199336306 cites W3125222626 @default.
• W3199336306 cites W3155580267 @default.
• W3199336306 doi "https://doi.org/10.1259/bjr.20210683" @default.
• W3199336306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34538073" @default.
• W3199336306 hasPublicationYear "2022" @default.
• W3199336306 type Work @default.
• W3199336306 sameAs 3199336306 @default.
• W3199336306 citedByCount "4" @default.
• W3199336306 countsByYear W31993363062022 @default.
• W3199336306 countsByYear W31993363062023 @default.
• W3199336306 crossrefType "journal-article" @default.
• W3199336306 hasAuthorship W3199336306A5008589447 @default.
• W3199336306 hasAuthorship W3199336306A5021638987 @default.
• W3199336306 hasAuthorship W3199336306A5027831576 @default.
• W3199336306 hasAuthorship W3199336306A5032217039 @default.
• W3199336306 hasAuthorship W3199336306A5038153105 @default.
• W3199336306 hasAuthorship W3199336306A5044140135 @default.
• W3199336306 hasAuthorship W3199336306A5054640090 @default.
• W3199336306 hasAuthorship W3199336306A5062168165 @default.
• W3199336306 hasAuthorship W3199336306A5083780722 @default.
• W3199336306 hasAuthorship W3199336306A5087739701 @default.
• W3199336306 hasBestOaLocation W31993363062 @default.
• W3199336306 hasConcept C121608353 @default.
• W3199336306 hasConcept C126322002 @default.
• W3199336306 hasConcept C126838900 @default.
• W3199336306 hasConcept C126894567 @default.
• W3199336306 hasConcept C141071460 @default.
• W3199336306 hasConcept C2776235491 @default.
• W3199336306 hasConcept C2779384505 @default.
• W3199336306 hasConcept C2780192828 @default.
• W3199336306 hasConcept C2781156865 @default.
• W3199336306 hasConcept C2989005 @default.
• W3199336306 hasConcept C509974204 @default.
• W3199336306 hasConcept C71924100 @default.
• W3199336306 hasConceptScore W3199336306C121608353 @default.
• W3199336306 hasConceptScore W3199336306C126322002 @default.
• W3199336306 hasConceptScore W3199336306C126838900 @default.
• W3199336306 hasConceptScore W3199336306C126894567 @default.
• W3199336306 hasConceptScore W3199336306C141071460 @default.
• W3199336306 hasConceptScore W3199336306C2776235491 @default.
• W3199336306 hasConceptScore W3199336306C2779384505 @default.
• W3199336306 hasConceptScore W3199336306C2780192828 @default.
• W3199336306 hasConceptScore W3199336306C2781156865 @default.
• W3199336306 hasConceptScore W3199336306C2989005 @default.
• W3199336306 hasConceptScore W3199336306C509974204 @default.
• W3199336306 hasConceptScore W3199336306C71924100 @default.
• W3199336306 hasIssue "1131" @default.
• W3199336306 hasLocation W31993363061 @default.
• W3199336306 hasLocation W31993363062 @default.
• W3199336306 hasLocation W31993363063 @default.

• next